SciSparc Subsidiary NeuroThera Secures Drug Batch Release for Phase IIb Tourette Trial

Bitget

News

Bitget2026/10/22 12:55

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SciSparc subsidiary NeuroThera Labs secured European batch release certification for SCI-110, enabling shipments for its FDA-approved Phase IIb Tourette syndrome trial.
All three study sites completed initiation activities, positioning the trial to begin enrolling adults; drug shipments are expected in the near term.
The study will evaluate SCI-110’s efficacy, safety and tolerability in adults with Tourette syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220855PRIMZONEFULLFEED9851167) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SciSparc Subsidiary NeuroThera Secures Drug Batch Release for Phase IIb Tourette Trial

You may also like

Crypto prices